Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy

Dickson, S. J.; Batson, S.; Copas, A. J.; Edwards, S. G.; Singer, M.; Miller, R. F.
November 2007
Thorax;Nov2007, Vol. 62 Issue 11, p964
Academic Journal
Background: Several studies have described improved outcomes for HIV-infected patients admitted to the intensive care unit (ICU) since the introduction of highly active antiretroviral therapy (HAART). A study was undertaken to examine the outcome from the ICU for HIV-infected patients and to identify prognostic factors. Methods: A retrospective study of HIV-infected adults admitted to a university affiliated hospital ICU between January 1999 and December 2005 was performed. Information was collected on patient demographics, receipt of HAART (no patient began HAART on the ICU), reason for ICU admission and hospital course. Outcomes were survival to ICU discharge and to hospital discharge. Results: 102 patients had 113 admissions to the ICU; HIV infection was newly diagnosed in 31 patients. Survival (first episode ICU discharge and hospital discharge) was 77% and 68%, respectively, compared with 74% and 65% for general medical patients. ICU and hospital survival was 78% and 67% in those receiving HAART, and 75% and 66% in those who were not. In univariate analysis, factors associated with survival were: haemoglobin (OR= 1.25, 95% CI 1.03 to 1.51, for an increase of 1 g/dl), CD4 count (OR = 1.59, 95% CI 0.98 to 2.58, for a 10-fold increase in cells/μl), APACHE II score (OR=0.51,95% CI 0.29 to 0.90, for a 10 unit increase) and mechanical ventilation (OR=0.29, 95% CI 0.10 to 0.83). Conclusions: The outcome for HIV-infected patients admitted to the ICU was good and was comparable to that in general medical patients. More than a quarter of patients had newly diagnosed HIV infection. Patients receiving HAART did not have a better outcome.


Related Articles

  • Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors. Hou-Hsien Chiang; Chien-Ching Hung; Chang-Min Lee; Hsuan-Yu Chen; Mao-Yuan Chen; Wang-Huei Sheng; Szu-Min Hsieh; Hsin-Yun Sun; Chao-Chi Ho; Chong-Jen Yu // Critical Care;2011, Vol. 15 Issue 4, p1 

    Introduction: Although access to highly active antiretroviral therapy (HAART) has prolonged survival and improved life quality, HIV-infected patients with severe immunosuppression or comorbidities may develop complications that require critical care support in intensive care units (ICU). This...

  • Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera/Eviplera) in the treatment of HIV infection. Bernardini, Claudia; Maggiolo, Franco // Patient Preference & Adherence;2013, Vol. 7, p531 

    The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a oncedaily, single-tablet regimen (STR) containing one nonnucleoside reverse-transcriptase inhibitor associated with two nucleos(t)ide reverse transcriptase inhibitors. It is approved by regulatory agencies (eg, US Food...

  • Inequality in Health Status Among Older Adults in Africa: The Surprising Impact of Anti-Retroviral Treatment. Negin, Joel; Nyirenda, Makandwe; Seeley, Janet; Mutevedzi, Portia // Journal of Cross-Cultural Gerontology;Dec2013, Vol. 28 Issue 4, p491 

    The article discusses a research to study the impact of antiretroviral therapy (ART) in improving health status and reducing mortality among people living with HIV (PLWH). The study confirms inequity observed in the PLWH especially older adults in Africa on ART and HIV-negative adults. The study...

  • Intensive Care Usage by HIV-Positive Patients in the HAART Era. Turtle, L.; Vyakernam, R.; Menon-Johansson, A.; Nelson, M. R.; Soni, N. // Interdisciplinary Perspectives on Infectious Diseases;2011, p1 

    In the 1980s the outlook for patients with the acquired immunodeficiency syndrome (AIDS) and critical illness was poor. Since then several studies of outcome of HIV+ patients on ICU have shown improving prognosis, with anti-retroviral therapy playing a large part. We retrospectively examined...

  • Pharmacotherapy of HIV: Focus on Etravirine. Lapadula, Giuseppe; Soria, Alessandro; Gori, Andrea // Clinical Medicine: Therapeutics;2009, Issue 1, p483 

    Etravirine (ETR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for binding to HIV reverse transcriptase in spite of most of the mutations which normally confer resistance to the other drugs of the same class. Evidences from clinical trials and post-marketing drug use...

  • Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. Gopal, Muralikrishna; Bhaskaran, Archana; Khalife, Wissam I.; Barbagelata, Alejandro // Current Cardiology Reviews;2009, Vol. 5 Issue 2, p149 

    HIV/AIDS (Human immunodeficiency virus/ Acquired immuno deficiency syndrome) is a growing global problem, in terms of its incidence and mortality. Patients with HIV/AIDS are living much longer with HAART (Highly active antiretroviral therapy) therapy so much so that HIV/AIDS has now become a...

  • Smear positive pulmonary tuberculosis among HIV patients receiving Highly Active Antiretroviral Therapy in Dar es Salaam, Tanzania. Bwana, Veneranda; Tenu, Filemoni; Magesa, Stephen M.; Mfinanga, Sayoki G. // Tanzania Journal of Health Research;Feb2011, Vol. 13 Issue 1, p17 

    Globally, tuberculosis-HIV co-infections are on the increase. In 2007, 15% (1.37 million) of the tuberculosis cases were HIV-positive tuberculosis (TB). This cross-sectional study was conducted in February 2009 to assess the effect of the level of CD4 lymphocyte counts on the development of...

  • Diagnosis of oral manifestations in HIV/AIDS patients who used HAART and developed diabetes mellitus. de Mello Silva, Adam; Correia dos Santos, Camila; Magdalena Giovani, Elcio // Brazilian Journal of Oral Sciences;Jul-Sep2012, Vol. 11 Issue 3, p352 

    To assess the prevalence of oral manifestations in HIV/AIDS patients and a possible correlation of the development of diabetes mellitus due to highly active antiretroviral therapy (HAART). Methods: 56 patients were examined, divided into two groups, Group 1, the HIV group, with 28 patients known...

  • Commentary on: Serum Albumin for Tuberculosis in HIV Infected Patients Eligible for Antiretroviral Therapy. Wiwanitkit, Viroj // BioImpacts;Dec2013, Vol. 3 Issue 4, p199 

    The author discusses the use of serum albumin as biochemistry parameter in the diagnosis of tuberculosis (TB) in HIV infected patients eligible for antiretroviral therapy. Topics discussed include usefulness of albumin as low-cost diagnostic tool in the detection of TB by G. Alvarez-Uria and...


Read the Article


Sign out of this library

Other Topics